The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 1.00 (5.714%)
Open: 18.00
High: 18.00
Low: 18.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

25 Mar 2022 14:36

RNS Number : 1109G
OptiBiotix Health PLC
25 March 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

PDMR Dealings

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure and diabetes, announces that it was notified today of the following share purchases made by René Kamminga, CEO of Optibiotix Ltd:

 

Date of transaction

Number of shares purchased

Price

23 March 2022

10,000

40p

24 March 2022

2,656

38p

 

 

Following the above transactions, Mr Kamminga is interested in 55,844 ordinary shares in the Company, representing 0.06 per cent. of the Company's issued share capital.

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

a.

Position/Status

PDMR

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 2p each

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 12,656 ordinary shares in the Company

 

c.

Price(s) and volume(s)

Price(s) per share

Volume(s)

40p

38p

10,000

2,656

d.

Aggregated information

- Volume

- Price

 

12,656

Average price of 39.6p

e.

Date of the transaction

23 and 24s March 2022

f.

Place of the transaction

London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSELFLIEESEDD
Date   Source Headline
14th May 20197:00 amRNSDistribution Agreement for SlimBiome® in Thailand
7th May 20197:00 amRNSLicense agreement for LPLDL®
2nd May 20197:00 amRNSInvestor evening
1st May 20197:00 amRNSSlimBiome launch to EU market at Vitafoods Europe
29th Apr 20197:00 amRNSFinal Results
24th Apr 20197:00 amRNSSlimBiome® Medical launches in UK market
11th Apr 20197:00 amRNSSlimBiome® receives approval from FSSAI in India
9th Apr 20197:00 amRNSSlimBiome® Medical agreement for Bulgaria
27th Mar 20193:18 pmRNSGrant of Options
27th Mar 20197:43 amRNSSweetBiotix®: Scientific and commercial update
27th Mar 20197:00 amRNSSweetBiotix®: Scientific and commercial update
25th Mar 201911:00 amRNSPrice Monitoring Extension
20th Mar 20197:00 amRNSExclusive distribution agreement for SlimBiome®
15th Mar 20197:00 amRNSExtension of term and territories for LPLDL®
13th Mar 20193:42 pmRNSExercise of Warrants
21st Feb 20197:00 amRNSLPLDL® determined GRAS by an Expert Panel in US
20th Feb 20197:00 amRNSPresentations at ProBiota - 2019
13th Feb 20197:00 amRNSTrading Statement
11th Feb 20197:00 amRNSDistribution agreement for LPLDL® in Japan
7th Feb 20197:00 amRNSSupply agreement for LPLDL® in the Baltic States
18th Jan 20191:56 pmRNSExercise of Warrants
11th Jan 20197:00 amRNSDirector Appointment
9th Jan 20197:00 amRNSDistribution agreement for CholBiome
7th Jan 20197:00 amRNSManufacturing agreement for SlimBiome®
17th Dec 20187:00 amRNSDirectorate Change
14th Dec 20187:00 amRNSIssue of Convertible Loan Notes by ProBiotix
5th Dec 20182:58 pmRNSHolding(s) in Company
4th Dec 20187:00 amRNSSlImBiome® Medical agreement for Greece and Cyprus
29th Nov 20187:00 amRNSSlimBiome Medical manufacturing agreement
27th Nov 20187:00 amRNSSlimBiome® granted medical device status & CE mark
22nd Nov 20187:00 amRNSCholBiome® agreement for Greece and Cyprus
11th Oct 20187:00 amRNSDirector's Dealing
9th Oct 20187:00 amRNSLPLDL® US manufacturing and supply agreement
8th Oct 20187:00 amRNSExercise of Options & Director's Dealing
3rd Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
1st Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
26th Sep 20187:00 amRNSDistribution agreement for CholBiome®
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 20187:00 amRNSFormation of ProBiotix Health Limited
10th Sep 20187:00 amRNSDirector Appointment
10th Sep 20187:00 amRNSLicence agreement with Bened Biomedical
10th Sep 20187:00 amRNSExercise of Warrants and Issue of Equity
4th Sep 20187:00 amRNSOptiBiotix signs US pharmaceutical deal
30th Aug 20187:00 amRNSHalf-year Report
6th Aug 20187:00 amRNSProposed directorate change
31st Jul 201810:04 amRNSDirector's dealing
17th Jul 20187:00 amRNSGrant of Options
12th Jul 20187:00 amRNSDirector's dealing
6th Jul 201812:00 pmRNSHolding(s) in Company
4th Jul 20182:07 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.